The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats

Steven T. Pittenger, Scott T. Barrett, Shinnyi Chou, Rick A Bevins

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Methamphetamine (meth) addiction is a costly burden to both the individual user and society as a whole. Establishing effective pharmacotherapies to treat meth dependence is needed to help solve this health problem. The study reported herein examined the effects of varenicline, a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in male Sprague-Dawley rats. Following indwelling jugular catheter surgery, rats were either trained to self-administer meth or saline on a variable ratio (VR) 3 schedule of reinforcement. Self-administration sessions (2 h duration; 19 total sessions) were conducted daily. The effect of varenicline pretreatment on meth and saline self-administration was then determined using a within-study design. All rats received varenicline (0.0, 0.3, 1.0, and 3.0 mg/kg) prior to 4 different test sessions. Dose order was randomly assigned and each test was separated by 2 standard self-administration sessions to assess stability of responding. Fifteen extinction sessions (no meth available) followed the last test. Extinction was followed by meth-primed (0.3 mg/kg IP) reinstatement tests to examine the effect of varenicline on meth-seeking behavior. All rats again received all doses of varenicline over 4 separate reinstatement tests performed on 4 consecutive days. Varenicline did not alter self-administration of meth or saline. Additionally, the 0.3 and 1.0 doses of varenicline non-specifically increased active lever responding during the reinstatement test sessions. This latter finding suggests that varenicline may increase relapse liability and should not be utilized as pharmacotherapy to treat meth dependence.

Original languageEnglish (US)
Pages (from-to)195-199
Number of pages5
JournalBehavioural Brain Research
Volume320
DOIs
StatePublished - Mar 1 2017

Fingerprint

Self Administration
Methamphetamine
Pharmaceutical Preparations
Varenicline
Reinforcement Schedule
Drug Therapy
Cholinergic Agonists
Indwelling Catheters
Nicotinic Receptors
Sprague Dawley Rats
Neck
Recurrence

Keywords

  • Addiction
  • Chantix
  • Drug dependence
  • Relapse
  • Reward enhancement

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats. / Pittenger, Steven T.; Barrett, Scott T.; Chou, Shinnyi; Bevins, Rick A.

In: Behavioural Brain Research, Vol. 320, 01.03.2017, p. 195-199.

Research output: Contribution to journalArticle

@article{0819d4b4ca6949c0ab4deb2b1910ba71,
title = "The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats",
abstract = "Methamphetamine (meth) addiction is a costly burden to both the individual user and society as a whole. Establishing effective pharmacotherapies to treat meth dependence is needed to help solve this health problem. The study reported herein examined the effects of varenicline, a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in male Sprague-Dawley rats. Following indwelling jugular catheter surgery, rats were either trained to self-administer meth or saline on a variable ratio (VR) 3 schedule of reinforcement. Self-administration sessions (2 h duration; 19 total sessions) were conducted daily. The effect of varenicline pretreatment on meth and saline self-administration was then determined using a within-study design. All rats received varenicline (0.0, 0.3, 1.0, and 3.0 mg/kg) prior to 4 different test sessions. Dose order was randomly assigned and each test was separated by 2 standard self-administration sessions to assess stability of responding. Fifteen extinction sessions (no meth available) followed the last test. Extinction was followed by meth-primed (0.3 mg/kg IP) reinstatement tests to examine the effect of varenicline on meth-seeking behavior. All rats again received all doses of varenicline over 4 separate reinstatement tests performed on 4 consecutive days. Varenicline did not alter self-administration of meth or saline. Additionally, the 0.3 and 1.0 doses of varenicline non-specifically increased active lever responding during the reinstatement test sessions. This latter finding suggests that varenicline may increase relapse liability and should not be utilized as pharmacotherapy to treat meth dependence.",
keywords = "Addiction, Chantix, Drug dependence, Relapse, Reward enhancement",
author = "Pittenger, {Steven T.} and Barrett, {Scott T.} and Shinnyi Chou and Bevins, {Rick A}",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.bbr.2016.12.005",
language = "English (US)",
volume = "320",
pages = "195--199",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",

}

TY - JOUR

T1 - The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats

AU - Pittenger, Steven T.

AU - Barrett, Scott T.

AU - Chou, Shinnyi

AU - Bevins, Rick A

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Methamphetamine (meth) addiction is a costly burden to both the individual user and society as a whole. Establishing effective pharmacotherapies to treat meth dependence is needed to help solve this health problem. The study reported herein examined the effects of varenicline, a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in male Sprague-Dawley rats. Following indwelling jugular catheter surgery, rats were either trained to self-administer meth or saline on a variable ratio (VR) 3 schedule of reinforcement. Self-administration sessions (2 h duration; 19 total sessions) were conducted daily. The effect of varenicline pretreatment on meth and saline self-administration was then determined using a within-study design. All rats received varenicline (0.0, 0.3, 1.0, and 3.0 mg/kg) prior to 4 different test sessions. Dose order was randomly assigned and each test was separated by 2 standard self-administration sessions to assess stability of responding. Fifteen extinction sessions (no meth available) followed the last test. Extinction was followed by meth-primed (0.3 mg/kg IP) reinstatement tests to examine the effect of varenicline on meth-seeking behavior. All rats again received all doses of varenicline over 4 separate reinstatement tests performed on 4 consecutive days. Varenicline did not alter self-administration of meth or saline. Additionally, the 0.3 and 1.0 doses of varenicline non-specifically increased active lever responding during the reinstatement test sessions. This latter finding suggests that varenicline may increase relapse liability and should not be utilized as pharmacotherapy to treat meth dependence.

AB - Methamphetamine (meth) addiction is a costly burden to both the individual user and society as a whole. Establishing effective pharmacotherapies to treat meth dependence is needed to help solve this health problem. The study reported herein examined the effects of varenicline, a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in male Sprague-Dawley rats. Following indwelling jugular catheter surgery, rats were either trained to self-administer meth or saline on a variable ratio (VR) 3 schedule of reinforcement. Self-administration sessions (2 h duration; 19 total sessions) were conducted daily. The effect of varenicline pretreatment on meth and saline self-administration was then determined using a within-study design. All rats received varenicline (0.0, 0.3, 1.0, and 3.0 mg/kg) prior to 4 different test sessions. Dose order was randomly assigned and each test was separated by 2 standard self-administration sessions to assess stability of responding. Fifteen extinction sessions (no meth available) followed the last test. Extinction was followed by meth-primed (0.3 mg/kg IP) reinstatement tests to examine the effect of varenicline on meth-seeking behavior. All rats again received all doses of varenicline over 4 separate reinstatement tests performed on 4 consecutive days. Varenicline did not alter self-administration of meth or saline. Additionally, the 0.3 and 1.0 doses of varenicline non-specifically increased active lever responding during the reinstatement test sessions. This latter finding suggests that varenicline may increase relapse liability and should not be utilized as pharmacotherapy to treat meth dependence.

KW - Addiction

KW - Chantix

KW - Drug dependence

KW - Relapse

KW - Reward enhancement

UR - http://www.scopus.com/inward/record.url?scp=85006170222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006170222&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2016.12.005

DO - 10.1016/j.bbr.2016.12.005

M3 - Article

C2 - 27939341

AN - SCOPUS:85006170222

VL - 320

SP - 195

EP - 199

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

ER -